HC Wainwright Predicts Cytokinetics Q3 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Cytokinetics in a note issued to investors on Wednesday, February 25th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings of ($2.03) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $136.00 price target on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ FY2026 earnings at ($7.12) EPS, FY2027 earnings at ($5.12) EPS and FY2028 earnings at ($1.67) EPS.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same period in the prior year, the company posted ($1.26) EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis.

Other analysts have also issued research reports about the company. Royal Bank Of Canada boosted their price target on Cytokinetics from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Friday, February 20th. Citizens Jmp lifted their price target on shares of Cytokinetics from $88.00 to $96.00 and gave the company a “market outperform” rating in a report on Wednesday. B. Riley Financial increased their price objective on shares of Cytokinetics from $90.00 to $108.00 and gave the stock a “buy” rating in a research note on Wednesday, January 21st. JPMorgan Chase & Co. raised their price target on Cytokinetics from $70.00 to $74.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Finally, Leerink Partners increased their target price on Cytokinetics from $83.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday. Seventeen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.83.

Cytokinetics Price Performance

Shares of Cytokinetics stock opened at $62.63 on Friday. The stock has a market capitalization of $7.66 billion, a PE ratio of -9.59 and a beta of 0.54. Cytokinetics has a 1-year low of $29.31 and a 1-year high of $70.98. The company’s fifty day simple moving average is $64.21 and its 200-day simple moving average is $58.38.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Bank of Montreal Can lifted its stake in Cytokinetics by 1.2% in the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock worth $845,000 after purchasing an additional 160 shares during the last quarter. Kennedy Capital Management LLC increased its stake in Cytokinetics by 1.2% in the fourth quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock worth $838,000 after purchasing an additional 162 shares during the period. UMB Bank n.a. boosted its stake in shares of Cytokinetics by 10.6% during the third quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 169 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in shares of Cytokinetics by 46.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 171 shares in the last quarter. Finally, Vident Advisory LLC grew its stake in Cytokinetics by 1.4% in the fourth quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock worth $1,046,000 after purchasing an additional 234 shares in the last quarter.

Insider Activity at Cytokinetics

In other Cytokinetics news, Director Wendell Wierenga sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the completion of the transaction, the director owned 32,444 shares in the company, valued at $2,145,846.16. This trade represents a 38.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total value of $134,728.00. Following the completion of the sale, the executive vice president directly owned 138,552 shares in the company, valued at approximately $8,484,924.48. The trade was a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 151,385 shares of company stock valued at $9,817,158 in the last 90 days. 2.70% of the stock is currently owned by insiders.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reiterates a “Buy” and models near‑term quarterly EPS (Q1: -$1.57, Q2: -$1.61, Q4: -$1.89) while assigning a $136 price target — a substantial upside that supports longer‑term investor interest. HC Wainwright estimates
• Positive Sentiment: Analysts have been raising price targets: Citizens JMP to $96 (market outperform), Leerink Partners to $84 (outperform), and Needham to $85 (buy) — these upgrades add upward pressure on sentiment. Benzinga price target coverage
• Positive Sentiment: Zacks notes Cytokinetics is advancing Myqorzo launch plans after FDA activity and highlights a ~$1.22B cash position, which supports funding for commercialization and 2026 catalysts. Myqorzo launch & cash runway
• Positive Sentiment: Retail/permissioned coverage and bullish opinion pieces (e.g., Villanovan profile) are promoting a buy case based on pipeline and commercialization upside. Why Cytokinetics Is a Buy
• Neutral Sentiment: Q4 earnings call and transcript coverage are available for deeper read‑throughs of management commentary on margins, SG&A, and launch timing (useful for assessing execution risk). Earnings call transcript (InsiderMonkey) Earnings transcript (Seeking Alpha) Earnings transcript (Yahoo)
• Neutral Sentiment: Reported short‑interest data appears anomalous/zero in the latest release, so there’s no clear short‑squeeze signal from those figures. (No actionable short‑pressure evidence.)
• Negative Sentiment: Q4 results showed a slightly wider-than-expected loss (EPS -$1.50 vs. estimate -$1.48) and higher expenses year‑over‑year — a near‑term negative that likely pressured the stock despite revenue outperformance. Q4 results coverage

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.